Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus ZERVIATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus ZERVIATE.
ACUVUE THERAVISION WITH KETOTIFEN vs ZERVIATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
ZERVIATE (cetirizine ophthalmic solution) contains cetirizine, a selective histamine H1 receptor antagonist. It inhibits histamine-induced vasodilation and increased vascular permeability, leading to reduction of ocular itching associated with allergic conjunctivitis.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1 drop in each affected eye twice daily (approximately 8 hours apart).
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 3 hours; clinical context: supports twice-daily topical ocular dosing for allergic conjunctivitis.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70%) and metabolites; biliary/fecal elimination accounts for less than 20%.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine